Nikhil Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center, discusses the benefits and limitations of fixed-dose treatment regimens, such as the combination of fianlimab (formerly REGN 3767) and cemiplimab-rwlc (Libtayo) that is under investigation in the phase 3 HARMONY HEAD TO HEAD trial (NCT06246916) in patients with unresectable or metastatic melanoma.
2024
How to protect your skin from sun damage and cancer
A previous version of this article incorrectly said that skin cancer is diagnosed in 20 percent of Americans each year. It should have said that skin cancer is diagnosed in 20 percent of Americans in their lifetime. The article has been corrected.
Does Dabrafenib-Trametinib Improve Overall Survival in Melanoma?
In patients with resected stage III melanoma, adjuvant therapy with dabrafenib plus trametinib reduces the risk for death by 20% compared with placebo, though the overall survival benefit does not reach statistical significance.
Iovance submits EU marketing authorization for lifileucel for advanced melanoma
Iovance Biotherapeutics has submitted a marketing authorization application to the European Medicines Agency for lifileucel to treat advanced melanoma, the company announced in a press release.